𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase I trials of targeted anticancer drugs: a need to refocus

✍ Scribed by Borden, Ernest C.; Dowlati, Afshin

Book ID
118049554
Publisher
Nature Publishing Group
Year
2012
Tongue
English
Weight
89 KB
Volume
11
Category
Article
ISSN
1474-1776

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Concept of maximum tolerated systemic ex
Concept of maximum tolerated systemic exposure and its application to phase I-II studies of anticancer drugs
✍ Evans, William E. ;Rodman, John H. ;Relling, Mary V. ;Crom, William R. ;Rivera, πŸ“‚ Article πŸ“… 1991 πŸ› John Wiley and Sons 🌐 English βš– 653 KB

The traditional approach to conducting Phase I studies of anticancer drugs is to select a starting dosage for humans based on preclinical data (e.g., mg equivalent of 1/10 LD10 in mice), then empirically escalate dosages in cohorts of patients until the maximum tolerated dosage (MTD) is established.

Design of new anticancer drugs. I. Easy
Design of new anticancer drugs. I. Easy hetarynic access to dihydrodipyridopyrazines, a new family of antitumor agents
✍ Ivan Rodriguez; Catherine Kuehm-CaubΓ¨re; Karine Vinter-Pasquier; Pierre Renard; πŸ“‚ Article πŸ“… 1998 πŸ› Elsevier Science 🌐 French βš– 164 KB

Unprecedented dihydrodipyridopyrazines were easily obtained by hetarynic dimerization of 2-alkylamino-3-bromopyridines in the presence of the complex base NaNH2-tBuONa. A few chemical properties of these new heterocycles are reported, as well as their antitumoral activity.